Lung Cancer Trials Ask AI to find trials
WithdrawnNot applicableNCT03409341
Official study title

Personalizing Immune Checkpoint Inhibitor Therapy

Study summary

This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors and other standard of care approaches, predicts clinical response to these agents.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood and tumor tissue analysis, Clinical response.

The study team can explain what participation involves.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 24, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Holy Cross Hospital, Maryland

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Holy Cross Hospital, Maryland
Interventions being studied
Other: Blood and tumor tissue analysis, Clinical response.
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Metastatic or stage IV→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Subjects with lung cancer about to undergo diagnostic/excisional biopsy with the intent to receive therapy with immune checkpoint inhibitors
  • Availability of fresh tumor tissue removed at excisional biopsy or diagnostic biopsy
  • Informed consent
Reasons someone may not be able to joinExclusion criteria

Lack of informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Holy Cross HospitalSilver Spring, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 24, 2020. Always confirm current availability with the study team.

View original record ↗